SAR Placing

13 December 2010

                              Sareum Holdings plc
                          ("Sareum" or "the Company")

                  Trading Update and Placing to raise £250,000

Trading Update

The  Board of Sareum, the specialist  cancer drug discovery business, is pleased
with  the quality of data that its  cancer research programmes have generated in
2010 and  is  encouraged  by  the  number  of  discussions currently in progress
regarding their commercialisation. The Board believes that the progress in 2010
has led to Sareum's programmes becoming more competitive when positioned against
similar  products in  development by  other companies.  Encouraging results have
recently  been generated in  pre-clinical cancer models  which are on-going. The
Board  looks forward to fully analysing this  data and announcing the results in
the first quarter of 2011.

Placing

In  addition, the  Company is  pleased to  announce it  has conditionally raised
£250,000,  before expenses, by way of a  placing by Hybridan LLP of 125,000,000
new  ordinary shares of 0.025p each in the  capital of the Company (the "Placing
Shares") at 0.20p per share.

Sareum  intends to  use the  proceeds of  the placing  primarily to progress its
cancer research programmes.

Application  will be made to the London Stock Exchange for the Placing Shares to
be  admitted to  trading on  AIM and  it is  expected that admission will become
effective and trading will commence on 15 December 2010. The Placing Shares will
rank pari passu with the existing ordinary shares of the Company.

Following  the admission of  the Placing Shares  to trading on  AIM, the Company
will have a total of 1,400,597,713 shares in issue.

Dr Tim Mitchell, CEO of Sareum commented:

"This  placing with an institutional investor leaves the Company well funded for
the  foreseeable future,  and able  to make  further investments in its valuable
pipeline of "best-in-class" cancer research programmes."


Enquiries:

 Sareum Holdings plc

 Tim Mitchell                 01223 497 700



 Merchant Securities Limited (NOMAD)

 Simon Clements/Bidhi Bhoma   020 7628 2200



 Hybridan LLP (Broker)

 Claire Noyce                 020 7947 4350

















This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE

[HUG#1471468]